Aclaris therapeutics, inc. (ACRS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenue, net

4,227

6,151

1,683

-

-

-

-

Costs and expenses:
Cost of revenue

4,055

4,329

1,207

-

-

-

-

Research and development

64,899

60,841

35,804

33,476

15,339

6,507

3,488

Sales and marketing

671

170

85

3,295

-

-

-

General and administrative

27,156

25,591

18,948

11,796

5,328

2,026

1,769

Goodwill impairment

18,504

-

-

-

-

-

-

Amortization of definite-lived intangible

4,426

552

-

-

-

-

-

Total costs and expenses

115,285

90,931

56,044

-

-

-

-

Total operating expenses

-

-

-

48,567

20,667

8,533

5,257

Loss from operations

-111,058

-84,780

-54,361

-48,567

-20,667

-8,533

-5,257

Other income (expense), net

-2,484

2,676

2,070

488

104

16

-

Loss from continuing operations

-113,542

-82,104

-52,291

-

-

-

-

Loss from discontinued operations

-47,812

-50,634

-18,062

-

-

-

-

Loss before income taxes

-161,354

-132,738

-70,353

-48,079

-20,563

-

-

Income taxes

-

-

-1,830

-

-

-

-

Interest income

-

-

-

-

-

-

21

Net loss

-161,354

-132,738

-68,523

-48,079

-20,563

-8,517

-5,236

Accretion of convertible preferred stock

-

-

-

-

2,566

2,054

1,740

Net loss attributable to common stockholders

-

-

-

-

-23,129

-10,571

-6,976

Net loss per share, basic and diluted

-3.90

-4.03

-2.44

-2.25

-3.79

-6.15

-6.45

Weighted average common shares outstanding, basic and diluted (in shares)

41,323

32,909

28,102

21,415

6,107

1,720

1,081

Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax of $0

28

145

-121

105

-148

-9

3

Foreign currency translation adjustments

-25

32

144

-225

5

-

-

Total other comprehensive income (loss)

3

177

23

-120

-143

-9

3

Comprehensive loss

-161,351

-132,561

-68,500

-48,199

-20,706

-8,526

-5,233

Contract research
Revenue, net

4,227

4,651

1,683

-

-

-

-

Other revenue
Revenue, net

-

1,500

-

-

-

-

-